Plandaí Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLPL research report →
Price Chart
About the company
Plandaí Biotechnology, Inc. does not have significant operations. Previously, it was involved in a biotechnology-related business.
- CEO
- Yi-Kuan Lin
- IPO
- 1995
- Employees
- 180
- HQ
- Taipei, TP, TW
Get TickerSpark's AI analysis on PLPL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.49M
- P/E
- -87.33
- PEG
- -0.87
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -87.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-51,401
- Net Income
- $-51,401-2001.4%
- EPS
- $0.00+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 9.73
- RSI (14)
- 45
- Avg Volume
- 2.36M
No earnings-call transcripts are available for PLPL yet.
- Free Float
- 98.8%
- Shares Outstanding
- 44.89B
- Float Shares
- 44.37B
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 1, 14 | JOHNSON BRIAN | other | 240,000 |
| Mar 30, 12 | JOHNSON BRIAN | other | 1,500,000 |
| Nov 17, 11 | JOHNSON BRIAN | other | 0 |
| Jan 1, 14 | RZEPNICKI DAVID | other | 500,000 |
| Mar 8, 12 | RZEPNICKI DAVID | other | 150,000 |
| Nov 17, 11 | RZEPNICKI DAVID | other | 0 |
| Jan 1, 14 | BAYLIS-DUFFIELD CALLUM | other | 1,000,000 |
| Feb 8, 13 | BAYLIS-DUFFIELD CALLUM | other | 0 |
| Jan 1, 14 | DUFFIELD DARON BAYLIS | other | 240,000 |
| Mar 8, 12 | DUFFIELD DARON BAYLIS | other | 450,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PLPL coverage
Recent articles, reports, and earnings notes.
No research on PLPL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PLPL report →